Select the Sequences That Matter
Geneious Biologics comes with a customizable system for filtering data that gives you the ability to assess whether a sequence is suitable for further research. Assign common sequence attributes with asset and liability scores and Geneious Biologics will use this information to create tables allowing you to quickly gauge a sequence’s potential.
Efficiently Compare Clusters
Compare sequences from multiple experiments within Geneious Biologics and minimize the risk of missing vital differences. Geneious Biologics generates graphs for easy reference helping you to visualize trends.
Link Assay and Sequence Data
Important information from assays can be linked directly to sequences by uploading CSV or Excel documents. This means that you no longer need to rely on disparate spreadsheets and important information is stored in the same location, giving you a more complete picture.
Focus on Areas of Interest
Choose how to cluster data according to your preferences and regions of interest, and Geneious Biologics will quickly generate tables. Re-clustering allows you to adjust similarity thresholds.
Standard databases are built into Geneious Biologics. Custom databases can be added accordingly.
Often you have to shoehorn a software solution into your process, the adaptability of Geneious Biologics was something we liked a lot. Once we knew what we could do with Geneious Biologics there was no other viable option.
We have been very pleased with the quality of the software, as well as with the interaction with Biomatters’ staff who have proven to be very responsive to technical questions and suggestions for further development.
Companies of our size and nature appreciate working with companies of the same mindset. The advantage with Geneious Biologics is – it is scientists talking to scientists.
One of the remaining bottlenecks to efficiently identify optimal antibody candidates is antibody sequence processing. Providing insight into large antibody sequence and data sets, such as can be retrieved from Isogenica’s fully synthetic human Fab or llamdA VHH domain antibody libraries, will speed up biologic drug development.
Geneious Biologics will allow our licensees to optimally use the data on the large number of leads retrieved from our libraries and, ultimately, enhance biologic drug development processes.
We are evolving from a cottage industry to an industrialized process, part of our challenge is ensuring our data maintains integrity and consistency with that evolution. We need software that can work with our unique Bicycle® platform and take our data quality to the next level.
New technologies like Geneious Biologics will play an important role in allowing researchers to better leverage existing molecular data sets.
Working with Geneious Biologics to apply this application to the analysis of our unique data sets has been enabling for Bicycle Therapeutics and I can see how this could drastically improve speed and accuracy in other areas of drug development.
Geneious Biologics allows us to drill into huge antibody sequence sets and quickly identify where errors lie and inspect bad clones. This will ensure we return the most effective, stable therapeutic antibody candidates to our clients, faster.
We are incorporating more high-throughput sequencing into our core business, and are screening increasingly large quantities of unique and complex VHH-based multi-specific biologics. Geneious Biologics will help us scale-up our screening efforts.